Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Similar documents
DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Differential Diagnosis of Hypokinetic Movement Disorders

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

Evaluation of Parkinson s Patients and Primary Care Providers

Basal ganglia motor circuit

III./3.1. Movement disorders with akinetic rigid symptoms

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Parts of the motor circuits

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Parkinson s Disease Update

Identification number: TÁMOP /1/A

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Atypical parkinsonism

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

Update on functional brain imaging in Movement Disorders

UNDERSTANDING PARKINSON S DISEASE

Parkinson s Disease and other related movement disorders a video guide to diagnosis

Movement Disorders: A Brief Overview

EBM Parkinson s Diseases

The PD You Don t See: Cognitive and Non-motor Symptoms

PARKINSON S DISEASE 馬 萬 里. Chinese character for longevity (shou) Giovanni Maciocia

Multiple choice questions: ANSWERS

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Parkinson s Disease Current Treatment Options

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Treatment of Parkinson s Disease: Present and Future

Issues for Patient Discussion

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

La neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

8/28/2017. Behind the Scenes of Parkinson s Disease

Hypokinetic Movement Disorders

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

Comprehensive Approach to DLB Management

Update on Parkinson s disease and other Movement Disorders October 2018

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

Form B3L: UPDRS Part III Motor Examination 1

Early Clinical Features of Parkinson s Disease and Related Disorders. Dr. Alastair Noyce

Visualization and simulated animations of pathology and symptoms of Parkinson s disease

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease

Clinical Features and Treatment of Parkinson s Disease

Optimizing Clinical Communication in Parkinson s Disease:

Enhanced Primary Care Pathway: Parkinson s Disease

The PD You Don t See: Cognitive and Non-motor Symptoms

Parkinsons Disease & Movement Disorder Aug 11-13, Frankfurt l Dr. Geeta Shroff

Pietro Cortelli. IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna

Objectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

Transcranial sonography in movement disorders

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Parkinson s Syndrome. Parkinson s Syndrome Goals & Objectives

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

L ecografia cerebrale: accuratezza diagnostica Dr Patrizio Prati Neurologia CIDIMU Torino

10th Medicine Review Course st July Prakash Kumar

Parkinson's Disease KP Update

Parkinson Disease. What causes the disease? Parkinson's disease occurs when nerve cells, or neurons, in an area of the brain known as the substantia

PD AND FALLS J U MALLYA FALLS AWARENESS MEETING

Using Resting-State Functional Connectivity of the Basal Ganglia as a Biomarker for Symptoms of Parkinson's Disease

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Joint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease

Evolution of a concept: Apraxia/higher level gait disorder. ataxia v. apraxia gait = limb apraxia. low, middle, high gait disturbance levels

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

Vague Neurological Disorders

Multiple System Atrophy

10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Imaging biomarkers for Parkinson s disease

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Accuracy in the clinical diagnosis of parkinsonian syndromes

Dementia: It s Not Always Alzheimer s

Examination of lalopathy and cognitive function in Parkinson's disease-associated diseases

Evaluation and Management of Parkinson s Disease in the Older Patient

Welcome and Introductions

STEADY YOUR APPROACH TO TREMOR (OVERVIEW OF DIFFERENTIAL DIAGNOSIS)

Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development

Parkinson disease What is Parkinson's disease? What causes the disease?

Freezing of gait in patients with advanced Parkinson s disease

Parkinson s Disease. Gillian Sare

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

Faculty. Joseph Friedman, MD

This is a free sample of content from Parkinson's Disease. Click here for more information or to buy the book.

MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS

Headway Victoria Epilepsy and Parkinson s Centre

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative

Disorders of gait and balance

Movement Disorders. Eric Kraus, MD! Neurology!

With Time, The Pathology of PD Spreads Throughout the Brain

Transcription:

Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle

Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non motor features Dementia

Disclosures Education grant from Boehringer. Slides from Orion Pharma.

Introduction Parkinson s disease A progressive and fluctuating neurological condition Associated with depletion of dopamine levels in the basal ganglia Dopamine is a neurotransmitter involved in initiation of movement, speech and selfexpression

Parkinson s Disease 0.2% population 2:1000 2% elderly population 10% nursing home

Aetiology Several different factors Genetic.Parkin,LRRK-2. Tau, synuclein Environmental Smoking Toxins - MPTP Trauma

Pathogenesis 70-80% loss of Dopamine producing cells in the basal ganglia Pathological marker Lewy bodies. Neuronal cell death mitochondrial dysfunction oxidative damage excitotoxicity inflammatory changes

Lewy Bodies

Diagnosis Difficult - especially in the early stages No specific marker for disease, therefore a clinical diagnosis. Clinico-pathological studies 76% accurate UK clinical diagnostic criteria: 80% sensitive: 30% specific Levodopa or Apomorphine test not recommended

Are you sure its Parkinson s

Prodromal phase depression fatigue autonomic features frozen shoulder / back pain REM sleep disorder Hyposmia

Unusual motor features Clawing 1 foot long distance running swimming in circles Rolex sign Abnormal stillness when seated Poor timing leading to faulty dance steps rest tremor after yawning unexplained episodes gait festination and propulsion

Signs and symptoms motor Hypokinesia shuffling, hesitant gait mask-like face drooling soft, mumbled speech micrographia Rigidity cramp-like pain expressionless face cog-wheel rigidity Resting tremor tremor at rest but not when moving or sleeping

Signs and symptoms non-motor Autonomic problems orthostatic hypotension constipation increased sweating impotence Depression Dementia

UK Clinical Diagnostic Criteria

STEP 1: Parkinsonian Syndrome bradykinesia and at least 1 of the following: muscular rigidity 4-6Hz rest tremor postural instability

STEP 2 Exclusion Criteria Repeated strokes History encephalitis Oculogyric crisis Neuroleptic treatment at onset >1 affected relative Sustained remission Strictly unilateral after 3 years Supranuclear gaze palsy cerebellar signs early severe autonomic involvement early severe dementia Babinski sign cerebral tumour on CT 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

STEP3 Supportive positive criteria At least 3 or more Unilateral onset Rest tremor present progressive persistent asymmetry affecting side of onset most excellent response to L dopa severe L-dopa induced chorea L-dopa response for >5 years clinical course of >10 years

Clinical features that make diagnosis less likely Early instability and falls Pyramidal or cerebellar signs Downgaze palsy Early autonomic failure Early severe dementia

If its not Parkinson s what is it then?

Common Misdiagnosis Essential tremor postural tremor. Vocal or head Arteriosclerotic pseudoparkinson s Gait apraxia / Lower limb PD Elderly, hypertensive, cognitive impairment, predominantly lower limb Normal Pressure Hydrocephalus

Parkinsonian Syndromes MSA PSP Corticobasal degeneration Post encephalitic Drug induced

How bad it is and what have I got to look forward to?

Prognosis and rating of severity Rating scales include: Hoehn and Yahr Staging of Parkinson s disease Unified Parkinson s Disease Rating Scale (UPDRS) Schwab and England Activities of Daily Living Webster Rating Scales

Do I need a Scan or x-ray?

Imaging in PD CT / MRI scan - Structural vascular lesions PET 18 F dopa differentiates normal subjects( Research tool mainly) SPECT (DAT scan) differentiates essential tremor from PD